Key Highlights
•
Researchers found that plasma p-tau181, a biomarker typically linked to Alzheimer’s disease, is significantly elevated in patients with amyotrophic lateral sclerosis (ALS). This suggests that p-tau181 levels reflect peripheral nerve processes in ALS, offering a new, distinct biomarker that complements the well-known neurofilament light chain (NfL) to better track disease mechanisms.
Source →
•
A new study shows that combining a polygenic risk score (PRS) with a transcriptional risk score (TRS) from blood tests significantly improves the early detection of Alzheimer’s disease compared to using genetic risk alone. This integrated approach, which achieved an accuracy of 70.5%, could provide a more accessible and less invasive way to identify individuals at high risk for Alzheimer’s across different populations.
Source →
•
A recent commentary discusses the critical challenge of bridging the funding gap for developing new drugs to treat amyotrophic lateral sclerosis (ALS). Addressing this financial shortfall is essential to accelerating the creation of effective therapies for this devastating neurological disorder.
Source →
Stay curious. Stay informed —
Science Briefing
